PAB Share Price

Open 0.01 Change Price %
High 0.01 1 Day 0.00 0.00
Low 0.01 1 Week 0.00 0.00
Close 0.01 1 Month 0.00 0.00
Volume 7500 1 Year 0.00 0.00
52 Week High 0.01
52 Week Low 0.00
PAB Important Levels
Resistance 2 0.01
Resistance 1 0.01
Pivot 0.01
Support 1 0.01
Support 2 0.01
ASX Australia Most Active Stocks
AKK 0.01 0.00%
GPP 0.03 0.00%
IMU 0.01 0.00%
IMU 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
DUE 2.74 16.60%
DUE 2.74 16.60%
PDN 0.06 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AHN 0.04 100.00%
AZS 0.03 50.00%
AZS 0.03 50.00%
PMQ 0.03 50.00%
NGY 0.05 25.00%
BIT 0.05 25.00%
BIT 0.05 25.00%
RAW 0.06 20.00%
RAW 0.06 20.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
BMN 0.02 -33.33%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
NMS 0.90 -23.73%
More..

Patrys Ltd (ASX: PAB)

PAB Technical Analysis 5
As on 2nd Dec 2016 PAB Share Price closed @ 0.01 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.01 & Strong Buy for SHORT-TERM with Stoploss of 0.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
PAB Target for December
1st Target up-side 0.01
2nd Target up-side 0.01
3rd Target up-side 0.01
1st Target down-side 0.01
2nd Target down-side 0.01
3rd Target down-side 0.01
PAB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.patrys.com
PAB Address
PAB
Equitable House
Level 6
Melbourne, VIC 3000
Australia
Phone: 61 3 9670 3273
Fax: 61 3 9670 3247
PAB Latest News
Interactive Technical Analysis Chart Patrys Ltd ( PAB ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Patrys Ltd
PAB Business Profile
Patrys Limited, a clinical stage biotechnology company, together with its subsidiaries, develops natural human antibodies as therapies for cancer and other major diseases in Australia. The company’s clinical products include PAT-SM6, a natural human antibody used for the treatment of multiple types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1 for treating gastric cancer and solid tumors. It also has late stage preclinical products, such as PAT-LM1, a natural human antibody that is used in the treatment for multiple types of cancer against colon, lung, breast, ovary, and pancreatic cancers. The company was founded in 2006 and is headquartered in Melbourne, Australia.